Biopharmaceutical News and Research

RSS

Novel lipid bubble delivery shows promise for ALS treatment

A researcher at the University of Missouri has made a promising breakthrough in the quest to help people with amyotrophic lateral sclerosis (ALS), the neurodegenerative disorder commonly known as Lou Gehrig's disease.

26 Feb 2026

Innovative laser procedure offers new hope for recurrent brain tumors

High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns after the tumor is removed, making it difficult to treat. Patients

26 Feb 2026

Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6 M from AMR Action Fund, extending the Company's Series A round to £30 M.

24 Feb 2026

Harnessing AI to optimize the development of new protein manufacturing processes

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

17 Feb 2026

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

Tahoe Therapeutics - a biotech start-up based in San Francisco, California - is creating the largest ever atlas of cell-chemical interactions to inform drug discovery. Combining automated pipetting systems from INTEGRA Biosciences, Parse Biosciences' Evercode™ single-cell RNA sequencing (scRNA-seq) products, and its own proprietary AI algorithms, the company already has several drug discovery programs running in parallel across multiple cancer types, and is expanding into other therapeutic areas.

12 Feb 2026

Astoriom acquires Precision Stability Storage

Astoriom, a global leader in scientific research and consumer product sample stability and biorepository storage, has expanded its sample management capabilities in the US with the acquisition of Precision Stability Storage.

27 Jan 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 - Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk.

21 Jan 2026

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center describes the chemical journey of YCT-529, a non-hormonal male birth control pill, and the promising molecular science behind it.

12 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From Collaborative Drug Discovery, Inc. 10 Jan 2026

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

18 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

$EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy$

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead program EPY201 through Phase 1/2a clinical trials.

10 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The Journal of Cystic Fibrsosis.

9 Dec 2025

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based Cellgorithm technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.

5 Dec 2025

Maximizing bioprocess efficiency through real-time cell density monitoring

Discover how real-time cell density monitoring boosts yield, lowers media costs, and improves viability in bioprocessing.

From Hamilton AG 5 Dec 2025

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

From Rentschler Biopharma SE 2 Dec 2025

Biopharmaceutical News and Research

Novel lipid bubble delivery shows promise for ALS treatment

Innovative laser procedure offers new hope for recurrent brain tumors

Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate

Harnessing AI to optimize the development of new protein manufacturing processes

Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies

Astoriom acquires Precision Stability Storage

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

Proimmune introduces Mastering Immunity 2026 - Shanghai symposium to address key immunogenicity challenges

New publication describes the chemical journey of non-hormonal male birth control pill

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Maximizing bioprocess efficiency through real-time cell density monitoring

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

AR3-based optogenetic strategy shows high efficacy in inducing apoptosis and antitumor effects

UCI Health launches clinical trial to test investigational cell therapy for lupus

Advanced workflow automation and scalable image analysis in spatial biology

How to optimize your cell line development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News